Lara Longpre's most recent trade in Mirum Pharmaceuticals Inc was a trade of 847 Common Stock done at an average price of $26.2 . Disclosure was reported to the exchange on Feb. 2, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Mirum Pharmaceuticals Inc | Longpre Lara | CHIEF DEVELOPMENT OFFICER | 02 Feb 2024 | 847 | 104,407 (0%) | 0% | 26.2 | 22,184 | Common Stock | |
| Mirum Pharmaceuticals Inc | Lara Longpre | CHIEF DEVELOPMENT OFFICER | 23 Jan 2024 | 32,000 | 32,000 | - | - | Stock Option (right to buy) | ||
| Mirum Pharmaceuticals Inc | Longpre Lara | CHIEF DEVELOPMENT OFFICER | 23 Jan 2024 | 8,000 | 8,000 | - | - | Restricted Stock Units | ||
| Mirum Pharmaceuticals Inc | Longpre Lara | CHIEF DEVELOPMENT OFFICER | 08 Jan 2024 | 1,019 | 105,254 (0%) | 0% | 28.0 | 28,568 | Common Stock | |
| Mirum Pharmaceuticals Inc | Lara Longpre | Chief Development Officer | 10 Nov 2023 | 434 | 106,273 (0%) | 0% | 22.3 | 9,673 | Common Stock | |
| Mirum Pharmaceuticals Inc | Lara Longpre | Chief Development Officer | 03 Jul 2023 | 1,004 | 105,839 (0%) | 0% | 25.6 | 25,749 | Common Stock | |
| Mirum Pharmaceuticals Inc | Lara Longpre | Chief Development Officer | 10 May 2023 | 684 | 106,843 (0%) | 0% | 16.9 | 11,576 | Common Stock | |
| Mirum Pharmaceuticals Inc | Lara Longpre | Chief Development Officer | 31 Jan 2023 | 38,500 | 38,500 | - | - | Stock Option (right to buy) | ||
| Mirum Pharmaceuticals Inc | Lara Longpre | Chief Development Officer | 31 Jan 2023 | 9,625 | 106,159 (0%) | 0% | 0 | Common Stock | ||
| Mirum Pharmaceuticals Inc | Lara Longpre | Chief Development Officer | 10 Nov 2022 | 82 | 96,534 (0%) | 0% | 17.0 | 1,398 | Common Stock | |
| Mirum Pharmaceuticals Inc | Lara Longpre | Chief Development Officer | 10 May 2022 | 1,454 | 96,452 (0%) | 0% | 13.6 | 19,725 | Common Stock | |
| Mirum Pharmaceuticals Inc | Lara Longpre | Chief Development Officer | 06 Jan 2022 | 60,000 | 60,000 | - | - | Stock Option (right to buy) | ||
| Mirum Pharmaceuticals Inc | Lara Longpre | Chief Development Officer | 06 Jan 2022 | 10,000 | 94,998 (0%) | 0% | 0 | Common Stock | ||
| Mirum Pharmaceuticals Inc | Lara Longpre | Chief Development Officer | 10 Nov 2021 | 753 | 84,998 (0%) | 0% | 13.5 | 10,177 | Common Stock | |
| Mirum Pharmaceuticals Inc | Lara Longpre | Chief Development Officer | 10 May 2021 | 1,259 | 77,081 (0%) | 0% | 14.6 | 18,407 | Common Stock | |
| Mirum Pharmaceuticals Inc | Lara Longpre | Chief Development Officer | 07 Jan 2021 | 65,000 | 65,000 | - | - | Stock Option (right to buy) | ||
| Mirum Pharmaceuticals Inc | Lara Longpre | Chief Development Officer | 10 Nov 2020 | 822 | 75,822 (0%) | 0% | 15.3 | 12,549 | Common Stock |